| Date | Title | Description |
| 13.08.2026 | Bora Group Posts Record 2Q26 Revenue and Strong Profits as Margins expand and Operations Resume Demand-Driven Growth | HONG KONG SAR – Media OutReach Newswire – 13 August 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 2Q2026 and provides full year outlook update.
2Q26 Busin... |
| 09.07.2026 | MacroGenics Completes $122.5 Million Sale Of GMP Manufacturing Operations To Bora Pharmaceuticals | MacroGenics announced that it has completed the sale of its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million before transaction fees, expenses, and customary post-closing a... |
| 17.06.2026 | Type 1 Diabetes in Children: FDA Approves Tzield to Slow Immune Attack After Diagnosis | By Maxwell Templeton
Published: Jun 17 2026, 13:49 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 13.06.2025 | Bridging Gaps in Healthcare: The Rise of Innovative Therapies in Asia-Pacific | In the ever-evolving landscape of healthcare, partnerships often pave the way for groundbreaking advancements. Recent developments from Specialised Therapeutics and VivaVision Biotech illustrate this trend vividly. Both companies are carvin... |
| 13.06.2025 | Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions | SINGAPORE, June 13, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, ... |
| 09.09.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 9, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (... |
| 02.09.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 2, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (... |
| 24.08.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 24, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (... |
| 16.08.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 16, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (... |
| 08.08.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 8, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (t... |
| 01.08.2024 | MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7... |
| 07.03.2024 | MacroGenics Provides Update on Corporate Progress and 2023 Financial Results | - |
| 08.03.2023 | MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million | - |
| 15.02.2022 | MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call | ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today an... |
| 26.10.2021 | MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call | ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today an... |
| 16.09.2021 | MacroGenics : Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 (Form 8-K) | MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
•21 of 40 patients (53%) achieved confirmed responses b... |
| 16.09.2021 | MacroGenics : Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021 | 21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A
78% of patients had tumor shrinkage at first scan
Median duration of... |
| 16.09.2021 | MacroGenics : Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress | Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial resp... |
| 13.09.2021 | MacroGenics : Announces Presentations at ESMO 2021 Virtual Annual Congress | ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today a... |
| 08.09.2021 | 'Like a kid in a candy shop': Michael Ehlers gets behind RNA 'copy machine' tech | Nathaniel Wang
Nathaniel Wang and Andrew Geall spent years working on self-replicating RNAs at Synthetic Genomics and Novartis Vaccines, respectively, before they realized they were coming at it the wrong way.
“For years an... |
| 08.09.2021 | A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round | Tachi is gone, but his legacy biotechs are continuing to make news.
This morning it’s the newly born HilleVax — a creation of Takeda and Frazier Healthcare Partners, where Tachi Yamada was respectively CSO and a longtime partner — that’s ta... |
| 08.09.2021 | Looking for fresh start following a Duchenne disaster, Catabasis rebrands; Huadong and Insilico team up in oncology | The leaders of Catabasis Pharmaceuticals have decreed that the biotech’s name is no more. Catabasis will be rebranding to Astria Therapeutics effective immediately, with the company’s stock ticker being updated on ... |
| 08.09.2021 | A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round | Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last winter based on a head-to-head matchup with breast cancer titan Herceptin. Now, a fuller look at Margenza’s survival data months after that a... |
| 08.09.2021 | Moderna surfaces as the first partner for Jim Wilson's rare disease nonprofit, donating an mRNA program at no cost | Top biopharma execs from Merck, Eli Lilly, Takeda and industry lobbying group PhRMA tried their best to persuade the media Wednesday that drug price negotiation bills making their way through Congress this month will be catastrophic for the... |
| 30.08.2021 | MacroGenics : Phase 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (TiP) | Phase 2 Trial of Enoblituzumab Plus Retifanlimab or Tebotelimab in First-Line Treatment of Patients
with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Poster #926TiP
NCT04634825
Gregory Obara,1 Jichao Sun,2 Deryk Loo,3 Chet ... |
| 22.07.2021 | MacroGenics : Announces Date of Second Quarter 2021 Financial Results Conference Call | ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today an... |
| 20.05.2021 | MACROGENICS, INC.
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting | Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patients
Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of sev... |
| 23.03.2021 | MacroGenics : Enhanced HER2-dependent immune activation by margetuximab supports combination with checkpoint blockade | Enhanced HER2-dependent Immune Activation by Margetuximab, an Investigational Fc-engineeredanti-HER2 mAb, 1555
Supports Combination with Checkpoint Blockade Zhang, X., Li, H., Yang, Y., Xu, Q., Kaufman, T., Smith, D., Nordstrom, J., Bonvini... |
| 28.12.2020 | MacroGenics : CELL REPORTS MEDICINE 2020 - Development and Preliminary Clinical Activity of PD- 1-Guided CTLA-4 Blocking Bispecific DART Molec | Article
Development and Preliminary Clinical Activity of PD-
1-GuidedCTLA-4 Blocking Bispecific DART
Molecule
Graphical Abstract
PD-1+ CTLA-4+ PD-1+
CTLA-4+
Authors
Alexey Berezhnoy, Bradley J. Sumrow,
Kurt Stahl, ..., Gundo Diedrich,
Ezio B... |
| 16.12.2020 | MacroGenics scores first FDA approval with breast cancer med Margenza in third-line patients | In the sustainably hot oncology field, breast cancer has attracted some of the biggest players on the market, including blockbuster meds from Roche and Merck. Now, a new player has taken the field after the FDA gave a thumb... |
| 06.02.2019 | MacroGenics’ stock price more than doubles on successful breast cancer study | In a conference call to discuss the results Wednesday morning, some analysts conceded that their forecasts of SOPHIA being a negative study did not come true, including one who said his firm was “dead wrong.”
Nevertheless, the company is be... |
| 10.12.2018 | FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns | On the Nasdaq, shares of MacroGenics, which closed Friday at $16.41, fell more than 25 percent in after-hours trading following the news.
The company said the hold was due to the company reporting liver toxicity events in the monotherapy tr... |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companies | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ... |
| 27.04.2017 | MacroGenics Raises $23.6M | A clinical-stage biopharmaceuticals company raised $23.6 million by selling 1.1 million shares to an investor, according to a filing with the Securities and Exchange Commission.
MacroGenics Inc. entered the agreement with an investor not af... |
| 27.04.2017 | MacroGenics Raises $23.6M | A clinical-stage biopharmaceuticals company raised $23.6 million by selling 1.1 million shares to an investor, according to a filing with the Securities and Exchange Commission.
MacroGenics Inc. entered the agreement with an investor not af... |
| 12.09.2016 | Protocols: Tillman Gerngross's Avitide goes back to the well for more venture cash; Novartis leads $17M startup round | Avitide CEO Kevin Isett
A year ago, Avitide CEO Kevin Isett told me that a $7.6 million round would be plenty to take the protein therapeutic company to profitability. But that calculation may have been off by a little. Thi... |
| 01.11.2013 | OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014 | Looking back 5 to 6 years, healthcare venture capital funds raised $7.8 billion, but last year they only raised $2.5 billion.
Silverstein and Carl Gordon, a partner and co-head of global private equity, told MedCity News they anticipate ple... |
| 12.09.2013 | Rockville biotech firm MacroGenics files for IPO | Rockville-based biotech company MacroGenics filed for a $60 million initial public offering on Sept. 4.
The Washington Business Journal reports:
MacroGenics, a clinical-stage biotech focused on oncology, said it would use the proceeds to fu... |
| 05.09.2013 | MacroGenics trumpets cancer immunotherapies in $60M IPO pitch | MacroGenics CEO & co-founder Dr. Scott Koenig
MacroGenics has taken aim at an initial public offering, joining the crowded ranks of biotech companies that either have or plan to hit the public markets this year. The Rockville, MD-based ... |
| 19.10.2007 | Life sciences briefing: Friday, Oct. 19, 2007 | Featured companies: DirectFlow, Direvo, Indigo Biosystems, MacroGenics
Direct Flow raises $27M for heart-valve implants — Santa Rosa, Calif.-based Direct Flow Medical, a startup developing heart implants, raised $27 million in a second fund... |
| - | MacroGenics’ stock price more than doubles on successful breast cancer study | Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.
Rockville, Maryland-based MacroGen... |
| - | FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns | The Food and Drug Administration placed two clinical trials of a bispecific monoclonal antibody under development for several solid tumor indications on hold due to concerns about liver toxicity.
Rockville, Maryland-based MacroGenics said F... |
| - | OrbiMed closes its largest VC fund, predicts rebound in healthcare investing in 2014 | OrbiMed has closed its largest venture capital healthcare fund to date as two partners predict a resurgence in biotech investment next year. The robust reception biotech initial public offerings have received this year is fueling this trend... |
